RESEARCH DOSSIER
Ketamine, Esketamine, and Rapid-Acting Glutamatergic Treatment
Abstract. Ketamine, esketamine, and related rapid-acting glutamatergic interventions form a major research field connecting NMDA-receptor pharmacology, plasticity hypotheses, experimental psychology, and clinical treatment of depression. This fundamental critical narrative monograph reconstructs the history from early randomized intravenous ketamine studies to controlled intranasal esketamine programs, monotherapy trials, comparative treatment research, and long-term extension studies. It distinguishes racemic ketamine from S-ketamine, short-term symptom response from relapse prevention, and reduced suicidal-ideation scores from demonstrated prevention of suicidal behavior or death. The synthesis evaluates molecular hypotheses involving AMPA signaling, mTOR-associated synaptic changes, metabolites, and opioid-system perturbation, alongside trial masking, active controls, selection, safety, repeated exposure, abuse liability, and regulatory differences between the United States and Europe. Current evidence supports rapid improvement in depressive symptoms in defined randomized populations, with differences in effect size and durability across designs. Mechanistic mediation, long-term comparative benefit, late harms, treatment selection, and implementation remain active scientific problems. The method is a referenced critical narrative synthesis of primary trials, experimental reports, systematic reviews, and official labeling; it is not a registered systematic review, original clinical study, or a source of individualized prescribing advice.
Keywords: ketamine; esketamine; rapid-acting antidepressants; glutamate; NMDA receptor; AMPA receptor; treatment-resistant depression; psychopharmacology; neuroplasticity; mTOR; hydroxynorketamine; intravenous ketamine; intranasal esketamine; clinical trials; suicidal ideation; relapse prevention; dissociation; pharmacokinetics; long-term safety; REMS; comparative effectiveness
Introduction: The Scientific Problem of Rapid Glutamatergic Treatment
Rapid-acting glutamatergic treatment designates therapeutic interventions whose acute pharmacological action engages glutamate-related signaling and whose clinically relevant psychological outcomes may become measurable within hours or days. Ketamine is the best-studied example in depression; esketamine is its S-enantiomer developed as a regulated intranasal antidepressant. Their importance arises from the convergence of an unusual temporal clinical profile with an experimentally tractable neurobiological perturbation. The study of these compounds asks whether modification of excitatory neurotransmission can initiate durable changes in depressive symptoms, subjective experience, and behavioral functioning, and whether a molecular event can be causally connected to a clinical outcome. A rapid score change is an observation; its explanation requires additional experiments. Berman et al. (2000) Zarate et al. (2006b) Li et al. (2010)
The object of this monograph is the pharmacology, experimental psychology, clinical evidence, safety, and epistemology of ketamine- and esketamine-based rapid treatment. It covers molecular target engagement, proposed downstream mechanisms, human trials for treatment-resistant major depression, acute suicidal ideation, maintenance, comparative effectiveness, safety, regulatory boundaries, and exploratory applications. It compares controlled research with clinical implementation without translating population-level findings into individual prescribing instructions. Classical serotonergic psychedelics, routine antidepressant pharmacodynamics, general theories of glutamate, and anesthetic uses are considered where necessary to explain this specific intervention class. Ketamine for obsessive-compulsive symptoms is evaluated as a distinct emerging hypothesis rather than being assimilated into the evidence for depression. Popova et al. (2019) Daly et al. (2019) Rodriguez et al. (2013)
The method is a critical narrative synthesis of accessible original controlled trials, experimental neuroscience, pharmacological and regulatory documents, and systematic reviews. Trial results are interpreted according to allocation, masking, comparator, population, endpoint, statistical precision, and duration. Mechanistic animal experiments establish experimentally bounded hypotheses; they cannot independently establish the mechanisms of clinical recovery in humans. Regulatory language is reported for its jurisdiction and date. The present work makes no claim to a registered systematic-review protocol, exhaustive literature search, individual-patient meta-analysis, original human experimentation, or external clinical peer review. The synthesized conclusion is conditional but substantial: rapid antidepressant symptom reduction is reproducibly observable in defined populations, while durability, mediation, safety over years, and equitable access remain distinct research questions. Murrough et al. (2013a) Fountoulakis et al. (2025) DailyMed (2026)
Definitions, Agents, and the Pharmacological Research Object
Ketamine is a chiral arylcyclohexylamine usually administered clinically as a racemic mixture of R- and S-ketamine when employed in intravenous depression trials. Esketamine is S-ketamine, sold as a specific intranasal prescription product in the United States and Europe. These designations identify chemical composition as well as materially different trial and authorization histories. Differences in route, bioavailability, procedural setting, and cointerventions prevent simple substitution of outcome estimates from one formulation to the other. A study of intravenous racemic ketamine therefore answers a different intervention question from a study of intranasal esketamine plus a newly initiated oral antidepressant. Berman et al. (2000) Popova et al. (2019) DailyMed (2026)
An NMDA receptor antagonist modifies one family of glutamate-gated ion channels. Competitive, noncompetitive, open-channel, and use-dependent forms of antagonism require specific pharmacological descriptions; both ketamine and esketamine are described in regulatory materials as noncompetitive NMDA receptor antagonists. AMPA receptor activation, synaptic protein synthesis, neurotrophin signaling, and plasticity are candidate downstream elements of some rapid effects. Neither the label NMDA antagonist nor a measured change in synaptic markers specifies one complete, exclusive antidepressant mechanism. Molecular efficacy, subjective dissociation, and relief on a symptom scale occupy different explanatory levels. Li et al. (2010) Zanos et al. (2016) DailyMed (2026)
Treatment-resistant depression is operationally defined in many trials by inadequate response to two or more adequate antidepressant treatments, with important variation in prospective confirmation, treatment duration, dose adequacy, and diagnostic exclusions. Response commonly means a prespecified reduction on a depression rating instrument; remission means falling below a defined symptom threshold; relapse means deterioration after an identified period of improvement. These constructs are study-specific. Major depression with acute suicidal ideation or behavior is a related but different clinical population, and a reduction in depressive symptom score cannot be treated as proof that suicide deaths or attempts are prevented. This distinction is explicit in current U.S. labeling. Popova et al. (2019) Daly et al. (2019) DailyMed (2026)
Historical Formation: From Anesthesia to the Glutamate Hypothesis
Ketamine entered medical practice as an anesthetic, and research on its dissociative and perceptual effects long preceded the development of antidepressant indications. Experiments with NMDA antagonism contributed to models of perception, altered consciousness, and psychopathology. By the late twentieth century, investigators examined whether disturbance of glutamate signaling could affect depressive states in a timescale distinct from that commonly observed with conventional antidepressant treatment. This history is best reconstructed from dated experiments rather than from hindsight that portrays a fully established mechanism at the moment of discovery. Initial clinical studies were small proof-of-concept investigations, deliberately exposing a previously underexplored therapeutic hypothesis to controlled observation. Berman et al. (2000) Zarate et al. (2006b)
In 2000 Berman and colleagues reported a randomized, double-blind, placebo-controlled crossover investigation in seven patients with major depression. Symptoms improved following ketamine compared with saline within the subsequent observation interval; the sample was too small to establish population-wide efficacy or enduring safety. In 2006 Zarate and colleagues reported a placebo-controlled crossover trial in 18 people with treatment-resistant depression, with depression differences apparent within hours and substantial effects at twenty-four hours. The latter study's large reported standardized contrast justified a larger research program but was intrinsically vulnerable to the instability of small-sample effect estimates and to masking difficulties associated with unmistakable psychoactive effects. Berman et al. (2000) Zarate et al. (2006b)
The next phase used larger parallel-group trials and increasingly demanding comparator strategies. Murrough and colleagues compared intravenous ketamine with the sedative midazolam in 73 randomized participants at two sites, strengthening interpretation relative to an inert-saline condition. Subsequent research addressed repeated dosing, intranasal delivery, adjunctive treatment, relapse prevention, active treatment comparison, and regulatory evaluation. The pivotal scientific transition was from asking whether any rapid antidepressant signal existed to estimating its incremental size, variability, duration, clinical relevance, and risks against meaningful alternatives. The appearance of different results under different comparator conditions is part of this history rather than a contradiction to be eliminated by averaging indiscriminately. Murrough et al. (2013a) Singh et al. (2016) Popova et al. (2019)
Glutamate, NMDA Receptors, and Circuit-Level Mechanisms
Glutamate is the principal excitatory neurotransmitter in many mammalian neural circuits, with NMDA and AMPA receptors contributing different temporal and biophysical properties to excitatory signaling. NMDA receptors are sensitive to voltage-dependent magnesium blockade and require coordinated conditions for channel opening; they are implicated in synaptic plasticity, although their consequences vary across cell types and circuits. Blocking these receptors can affect inhibitory interneurons, excitatory principal cells, network oscillations, and subsequent plasticity. A simplistic proposition that depression means uniformly excessive NMDA activity does not follow. The target is embedded in a dynamic system in which transient antagonism can produce context-dependent network changes. Li et al. (2010) Anand et al. (2000)
One influential account proposes that at some exposures NMDA blockade on inhibitory neurons permits a transient increase in cortical glutamatergic throughput, engaging AMPA-dependent signaling and downstream protein-synthesis pathways. This disinhibition model is compatible with several physiological findings but requires circuit-specific evidence and cannot be assumed as the unique route to human antidepressant response. Different interneuron classes, receptor subunits, basal states, and brain regions may generate different responses. Observations made during anesthesia, subanesthetic exposure, or a rodent behavioral experiment are not automatically equivalent. Translational claims should connect drug concentration, cellular perturbation, circuit readout, and clinically defined outcome across comparable timescales. Anand et al. (2000) Li et al. (2010)
Ketamine's psychologically conspicuous acute effects include dissociation, perceptual distortion, changes in time experience, and alterations in bodily awareness. These effects are important for safety, study masking, and the phenomenology of intervention. Whether the experience itself mediates later symptom improvement remains an empirical question. Dissociation could accompany relevant receptor engagement, be partly independent of antidepressant action, or influence expectations and subsequent ratings. Separating these possibilities requires valid acute-state measures, careful temporal sampling, pharmacological probes, and designs that avoid conditioning clinical outcome analyses on variables altered by treatment. A mechanistic narrative becomes stronger when it states what evidence would falsify its proposed mediating path. Murrough et al. (2013a) Williams et al. (2018) DailyMed (2026)
Synaptic Plasticity, mTOR Signaling, and Neurotrophic Hypotheses
Li and colleagues reported preclinical evidence that NMDA-antagonist exposure could rapidly stimulate mTOR-associated synaptic protein synthesis and synapse-related changes in a rodent prefrontal cortex model. These experiments shifted attention from an immediate receptor block to processes continuing after circulating drug concentrations decline. The proposal links a short pharmacological event to structural and functional adaptation, which is a plausible explanation for antidepressant effects lasting longer than the initial subjective intoxication. The experiments establish experimentally manipulable relationships in a particular preparation; direct proof that the identical pathway is necessary and sufficient in treated patients would require appropriately timed, target-specific human evidence. Li et al. (2010)
mTOR, brain-derived neurotrophic signaling, AMPA receptor throughput, and stress-associated synaptic remodeling are related but analytically distinguishable processes. A pathway could participate in a subset of neural adaptations without explaining why one patient responds, another experiences transient benefit, and a third does not. Rodent stress-based behavioral paradigms also measure specific patterns of behavior, not the full syndrome of human major depressive disorder. Causal language should therefore preserve the contrast between preventing a drug-induced laboratory phenotype by manipulating a pathway and proving that the same pathway mediates clinically significant remission. Independent replications, convergent methods, and exposure-matched controls are particularly valuable here. Li et al. (2010) Zanos et al. (2016)
Zanos and colleagues demonstrated in experimental systems that selected ketamine metabolites, notably hydroxynorketamine-related compounds, can produce antidepressant-like behavioral effects through mechanisms not reducible to straightforward NMDA receptor inhibition in their model. That finding generated a productive debate about parent-drug receptor antagonism, metabolite formation, and downstream glutamate receptor activity. It does not establish that a metabolite is an effective approved treatment for patients with depression. A disciplined translational program would characterize metabolite exposure, receptor selectivity, dose-response, behavioral assays, and human clinical outcomes independently. The lasting lesson is that the mechanism cannot be inferred solely from the initiating drug's most familiar receptor designation. Zanos et al. (2016) Li et al. (2010)
Alternative Molecular Accounts and Pharmacological Perturbation Tests
Evidence that opioid signaling may participate in some ketamine antidepressant responses emerged from a small human pharmacological challenge study by Williams and colleagues, who reported attenuation of the antidepressant effect when pretreatment involved the opioid antagonist naltrexone. The experimental logic is notable: a putative mediator is perturbed rather than merely correlated with symptom change. Yet a single small sample, differences in expectancy or tolerability, and the broad physiological consequences of opioid antagonism prevent an exclusive causal assignment. This proposal calls for adequately powered independent confirmation and careful differentiation of the neural process being blocked from nonspecific changes in treatment experience. Williams et al. (2018)
Other candidate explanations involve changes in inflammatory signaling, stress-related pathways, cortical excitation-inhibition balance, and activity-dependent synaptic adaptation. Such hypotheses can overlap rather than being independent competitor theories. Their relative explanatory weight depends on tests that measure candidate mediators before outcomes, manipulate them selectively, and show dose- and time-consistent relationships. A blood biomarker that changes after a dose may be a correlate, a consequence, or a response to nonspecific stress. Human neuroimaging readouts are also indirect proxies for particular neural processes. Naming a biomarker as the cause of symptom improvement requires evidence exceeding simple within-patient covariance. Li et al. (2010) Zanos et al. (2016)
A negative comparison drug provides a particularly informative contrast to the view that NMDA antagonism alone is a sufficient condition for robust rapid antidepressant efficacy. A placebo-controlled trial of memantine, another NMDA-active agent, did not establish the same striking efficacy signal seen in selected ketamine studies. Differences in binding kinetics, trapping, receptor access, dosing schedules, and pharmacological profiles may matter, but mechanistic explanation must be tested rather than inferred from a shared target category. The field therefore requires a pharmacology of interventions, not a taxonomy that equates any glutamate-targeting drug with an approved or proven rapid antidepressant. Zarate et al. (2006a) Zarate et al. (2006b)
Human Experimental Methods and Mechanistic Inference
Human studies can separately examine acute drug exposure, perceptual experience, neural physiology, depression ratings, functional recovery, and durability. Common approaches include randomized clinical trials, symptom scales such as the Montgomery–Åsberg Depression Rating Scale, clinician and patient reports, assessments of dissociation, repeated time-point sampling, and treatment follow-up. Each measure has its own construct: a change in a depression scale is not identical to occupational functioning, and a subjective altered state cannot by itself identify the molecular mediator. Research programs become more interpretable when outcome hierarchy and analysis populations are specified before results are known. Murrough et al. (2013a) Popova et al. (2019)
Functional magnetic resonance imaging, electroencephalography, magnetic resonance spectroscopy, and pharmacokinetic sampling provide complementary evidence, but the inference from an observed signal to a precise causal pathway is demanding. Changes in blood oxygenation, oscillatory power, or regional metabolite concentrations may reflect multiple underlying mechanisms. Within-person repeated measures can establish temporal association, yet are vulnerable to spontaneous symptom change, regression to the mean, carryover, and effects of concurrent treatment. Random allocation improves causal identification at the intervention level while still leaving mediation unclear. Mechanistic trials should state whether the target is treatment efficacy, proximal target engagement, or an exploratory biomarker rather than treating each endpoint as interchangeable. Popova et al. (2019) Daly et al. (2019)
Drug-induced dissociation makes conventional blinding difficult: participants and raters may infer assignment from perceptual and autonomic effects. Midazolam is an active control that provides some perceptible medication experience, but it has its own pharmacology and cannot match every feature of ketamine. The choice between saline, active control, oral antidepressant augmentation, and another established treatment therefore changes the causal estimand. Credibility ratings, blinded independent assessment, prespecified analytic strategies, negative controls, and replication across sites should be interpreted as substantive features of evidence quality. A pooled estimate from trials using fundamentally different comparators may answer an ambiguous question unless those distinctions are retained. Murrough et al. (2013a) Fountoulakis et al. (2025)
Trial Outcomes, Estimands, and the Meaning of Rapid Benefit
The adjective rapid describes the observation window, not the universality or persistence of treatment response. A study finding an average difference at twenty-four hours establishes a population comparison at that endpoint under its eligibility and intervention conditions. It does not establish that every participant experiences remission, that the effect persists indefinitely, or that treatment changes an underlying disease mechanism. Efficacy estimates depend on baseline severity, prior treatment failure, comorbidity, patient selection, placebo response, and concurrent care. This is particularly important in research enrolling people after prospective confirmation of prior nonresponse, as such enrichment may raise internal consistency while narrowing transportability. Zarate et al. (2006b) Popova et al. (2019)
Depression rating scales allow blinded and repeated symptom assessment, but they combine dimensions of mood, motivation, cognition, sleep, and somatic distress into a summary score. A trial can identify a statistically reliable mean difference without resolving which symptoms changed most, how participants describe improvement, or whether function improved to a personally meaningful degree. Remission, response, time to first improvement, sustained remission, hospitalization, and quality of life are analytically separate endpoints. Their confidence intervals, multiplicity control, missing-data assumptions, and adverse-event balances determine the appropriate strength of interpretation. Murrough et al. (2013a) Daly et al. (2019)
Clinical decision making also depends on how rapid benefit relates to burdens: supervised sessions, possible cardiovascular and perceptual effects, continuity of access, and the needs of patients with high immediate clinical risk. Evidence should distinguish an intervention capable of producing relatively prompt symptom relief from a comprehensive long-term treatment strategy. Comparisons with electroconvulsive therapy and other treatment-resistant depression approaches help establish relative benefits and harms, but their applicability is confined to the trial's actual population and protocol. The research question is an integrated benefit–burden estimand, not a universal ranking of interventions detached from clinical context. Anand et al. (2023) Reif et al. (2023)
The Controlled Evidence for Intravenous Racemic Ketamine
Early intravenous trials established the possibility of a rapid antidepressant signal under random allocation, but their evidence strength increased as design limitations were addressed. Berman and colleagues studied seven patients in 2000; Zarate and colleagues examined eighteen treatment-resistant participants in 2006. Both used a crossover format and placebo comparison, with symptom assessments shortly after infusion. Their chief historical contribution is proof of concept: an intervention engaging the glutamatergic system can precede measurable changes in depressive symptoms on a much shorter timeline than several conventional antidepressant trials. Small samples, possible treatment-guessing, crossover carryover, and limited follow-up restrict estimates of precision and generalizability. Berman et al. (2000) Zarate et al. (2006b)
Murrough and colleagues' 2013 randomized study compared ketamine with midazolam in seventy-three adults with treatment-resistant major depression. The adjusted twenty-four-hour MADRS difference favored ketamine by 7.95 points, with a 95 percent confidence interval from 3.20 to 12.71; response was reported in 64 percent of ketamine-assigned participants and 28 percent of the active-control group. These results supply a more informative counterfactual than comparison with an inert infusion alone, although dissociation and cardiovascular changes could still disclose assignment. The trial supports rapid antidepressant efficacy in the studied population and leaves durability after the acute phase, very rare harms, and the optimal comparative treatment pathway unresolved. Murrough et al. (2013a)
Repeated-dose studies moved beyond single-infusion efficacy. Singh and colleagues randomized treatment-resistant patients to different frequencies of intravenous ketamine or placebo, studying whether symptom improvement could be maintained through an initial treatment interval. Benefits in that controlled setting suggest that serial exposure can extend the short observation window of a single infusion. Such designs should not be conflated with evidence for indefinite administration, safe unattended use, or an established long-term dosing policy; their controlled phase is shorter than the years over which patients may require treatment. Treatment course, withdrawal, follow-up attrition, and cointerventions are integral to estimating whether an observed trajectory represents sustained benefit. Singh et al. (2016) Murrough et al. (2013b)
Development and Clinical Trial Architecture of Intranasal Esketamine
Intranasal esketamine was developed through a coordinated program of controlled depression trials, pharmacovigilance planning, and a supervised-administration model. The route changes delivery conditions and the molecule differs from racemic ketamine, so its evidentiary identity is independent even when the broad receptor class overlaps. Early clinical programs commonly introduced or optimized an oral antidepressant in both randomized groups while comparing active nasal esketamine with nasal placebo. The primary causal contrast is the additional effect of esketamine within a treatment package that already contains a concurrent antidepressant and structured clinical contact. This architecture is essential for interpreting both benefits and placebo-context responses. Popova et al. (2019) DailyMed (2026)
Popova and colleagues' 2019 randomized trial recruited adults with treatment-resistant nonpsychotic depression and prospectively checked previous nonresponse in the treatment episode. Of 435 screened, 227 were randomized and 197 completed the four-week double-blind phase. At day twenty-eight, the estimated least-squares mean difference in MADRS change was −4.0 points for esketamine plus a newly initiated oral antidepressant compared with nasal placebo plus an oral antidepressant, with a 95 percent confidence interval from −7.31 to −0.64. This demonstrated an incremental average benefit in that trial. Magnitude and clinical significance must be judged alongside baseline severity, uncertainty, adverse effects, and the fact that both groups were simultaneously receiving active treatment. Popova et al. (2019)
Trial reports frequently emphasize early separation from control, but the principal endpoint, prespecified testing sequence, and patient-important outcomes must remain explicit. A small mean difference at an early time may be meaningful for some severe cases while other participants experience no clinically relevant improvement. Repeated symptom observations require multiplicity management, and randomized trials with high-intensity visits have contextual features that differ from everyday services. Commercial sponsorship and the concentration of development trials within one program should be considered when interpreting independent replication. The scientific conclusion is strongest when positive trials, null or less persuasive outcomes, later meta-analysis, and alternative-treatment comparisons are examined together. Popova et al. (2019) Fountoulakis et al. (2025)
Esketamine Monotherapy and the Changing U.S. Evidence Base
The U.S. regulatory treatment indication for adult treatment-resistant depression expanded to permit intranasal esketamine either alone or with an oral antidepressant. This indication differs from the separate U.S. indication for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, where combination with an oral antidepressant remains specified. The distinction matters because an earlier scientific conclusion that an oral antidepressant is always required would now misrepresent the United States label. European authorization retains its own jurisdiction-specific conditions, including combination treatment for treatment-resistant depression. Regulatory comparison must therefore specify region and document date, not simply state that a medicine is globally approved for one uniform regimen. DailyMed (2026) European Medicines Agency (2025)
Janik and colleagues' placebo-controlled phase-four monotherapy trial, published in 2025, evaluated adult patients with treatment-resistant depression without simultaneous oral antidepressant therapy. In the efficacy analysis set, 378 participants received at least one dose of study drug and met the prespecified severity requirements. At twenty-eight days, the placebo-adjusted MADRS changes favored the two esketamine groups by −5.1 points (95 percent CI, −7.91 to −2.33) and −6.8 points (95 percent CI, −9.48 to −4.07); differences were also observed about twenty-four hours after initial administration. This directly evaluates the independent efficacy of the product in a specific sample rather than extrapolating from earlier adjunctive studies. Janik et al. (2025)
The monotherapy trial adds a valuable randomized comparison but retains the general limitations of psychoactive treatment studies: potential unmasking, selective eligibility, short blinded follow-up, and sponsor-linked study infrastructure. Open-label follow-up can describe outcomes among continuing participants but provides a weaker counterfactual than continued random allocation. The results should inform an updated scientific synthesis, while decisions about whom to treat, monitoring, contraindications, and long-term safety still require the contemporary prescribing information and qualified clinical judgment. A regulatory label is evidence of an authorization decision, not a guarantee of uniformly favorable outcomes for all patients bearing a broad diagnostic category. Janik et al. (2025) DailyMed (2026)
Continuation, Withdrawal, and Relapse Prevention
A fundamental distinction separates acute treatment response from prevention of subsequent relapse. Daly and colleagues' SUSTAIN-1 randomized-withdrawal study enrolled patients who had already achieved stable response or remission during esketamine treatment combined with an antidepressant, then randomized continuation of esketamine against discontinuation to nasal placebo under trial conditions. This design tests continued treatment among a selected group demonstrating earlier benefit and tolerability. It is informative for maintenance efficacy, but its estimate does not apply directly to all individuals who begin therapy or to patients who discontinued during the enrichment period. Daly et al. (2019)
The randomized-withdrawal method also requires careful attention to expectations, discontinuation phenomena, and how relapse is operationally defined. The contrast is continuation against withdrawal after a period of active exposure, not initial esketamine against never-treated patients. Such trials can overstate apparent applicability when discussed without this population-selection step. Maintenance outcomes need associated safety data, treatment burden, costs, and the existence of clinically meaningful alternative support. Longer periods of observation improve knowledge of recurrence but also introduce censoring and selection, especially when participants unable to tolerate treatment leave the study. Daly et al. (2019) Zaki et al. (2025)
The final SUSTAIN-3 open-label extension reports substantial cumulative treated exposure and follows people for longer than pivotal four-week trials. That is useful for detecting common events, persistence in a selected treated population, and some longitudinal patterns, while it lacks the same level of randomized counterfactual control and can be affected by survivorship bias. Participants who discontinue because of unfavorable experiences may be underrepresented in later assessments. Evidence that improvement persists among remaining participants cannot alone establish the long-term net comparative benefit of indefinite exposure. For a fully adequate maintenance science, randomized strategy trials, standardized late-harm monitoring, and patient-centered functional endpoints remain important. Zaki et al. (2025) Daly et al. (2019)
Comparative Effectiveness: Electroconvulsive Therapy and Other Strategies
Comparing ketamine with electroconvulsive therapy changes the reference question from superiority over placebo to effectiveness relative to an established, intensive intervention for severe depression. The ELEKT-D study randomized 403 people referred to electroconvulsive-therapy clinics who had treatment-resistant major depression without psychosis. Of those who actually initiated randomized treatment, 195 received intravenous ketamine and 170 electroconvulsive therapy. A three-week primary response assessment favored ketamine numerically, at 55.4 percent against 41.2 percent, and met the study's prespecified criterion for noninferiority. These data concern the tested nonpsychotic population and procedural designs, not every clinical indication for electroconvulsive therapy. Anand et al. (2023)
The trial was open-label and excluded people with psychosis, an important boundary because electroconvulsive therapy has particular clinical uses beyond that comparison. Patients and care teams could not be masked to procedures; withdrawals before starting treatment and differences in patient preference or tolerability may affect interpretation. Short-term cognitive testing showed a more pronounced memory-recall decline after electroconvulsive therapy, with later recovery trends, while dissociation was more prominent in the ketamine arm. A finding of noninferiority for one specified response endpoint should not be converted into global equivalence for all forms of depression, long-term relapse, safety, or patient preferences. Anand et al. (2023)
The ESCAPE-TRD trial compared intranasal esketamine with extended-release quetiapine, each alongside continuing antidepressant treatment, in adults with treatment-resistant depression. The randomized open-label, rater-blinded active comparison enrolled 676 participants. At eight weeks, remission was reported in 27.1 percent of the esketamine group and 17.6 percent of the quetiapine group. This addresses a relevant clinical choice more directly than a placebo-only trial; however, its unmasked treatment experience, different adverse-effect profiles, and sponsor-associated research demand cautious interpretation of functional and secondary outcomes. The best comparative evidence specifies precisely which alternatives, schedules, and endpoints are being compared. Reif et al. (2023)
Suicidal Ideation, Suicidal Behavior, and Acute Psychiatric Risk
The distinction between suicidal ideation as a rating-scale outcome and suicidal behavior as a rare, high-consequence event is central to this research field. Reducing reported suicidal thoughts within hours may offer important clinical opportunities, yet proving a reduction in suicide attempts or deaths requires different, often much larger and longer studies. Acute clinical management generally includes concurrent observation, supportive treatment, and safety interventions that influence outcomes. The current U.S. Spravato label explicitly states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated, even though depressive-symptom treatment is authorized for a defined high-risk major-depression population when combined with an oral antidepressant. DailyMed (2026) Canuso et al. (2018)
Canuso and colleagues investigated intranasal esketamine among patients at imminent risk of suicide with standard care and assessed rapid changes in depressive symptoms and suicidality-related measures. Such studies are clinically relevant but have design complications: emergent inpatient care and concurrent interventions are necessary and can influence both groups. A change in a depressive-symptom endpoint cannot be interpreted as direct evidence of preventing suicide. Differences in ideation-related exploratory outcomes and the temporal scope of follow-up must be analyzed separately. The ethical imperative to provide comprehensive care limits how an isolated drug effect can be studied in highly vulnerable populations. Canuso et al. (2018) DailyMed (2026)
Abbar and colleagues' multicenter French randomized trial enrolled 156 hospitalized adults experiencing severe suicidal ideation and compared intravenous ketamine with saline alongside usual care. The study provides controlled evidence for rapid change in the immediate ideation outcome in its clinical context, although diagnostic subgroups, sample sizes, and longer-term outcomes constrain inference. A 2026 systematic review and meta-analysis pooling randomized intravenous ketamine trials likewise reports short-term decreases in suicidal symptom measures, with uncertainty about longer-term outcomes. The correct synthesis recognizes evidence for symptom change while maintaining an explicit evidentiary boundary around suicide attempts, mortality, sustained protection, and treatment decisions made during crises. Abbar et al. (2022) Shim et al. (2026)
Systematic Reviews, Statistical Heterogeneity, and Competing Estimates
Systematic reviews summarize a larger body of evidence but may combine materially distinct interventions, comparators, designs, treatment settings, outcome times, and populations. An effect estimated for intravenous racemic ketamine shortly after one infusion is not directly interchangeable with an estimate for intranasal esketamine combined with a newly initiated antidepressant at four weeks. Standardized mean differences help compare scales, yet they conceal absolute changes and clinical interpretation, and are affected by between-study variation. A synthesis should therefore identify the clinical estimand before pooling or narratively comparing summary effects. Fountoulakis et al. (2025) Shim et al. (2026)
Fountoulakis, Saitis, and Schatzberg's 2025 PRISMA meta-analysis examined esketamine treatment evidence, raising questions about the magnitude of average symptom benefit and evidentiary support for suicidality claims. Its results should be weighed against primary randomized reports and differences in which trials and outcomes were eligible. A more conservative pooled estimate need not mean that every clinical trial is false; it may reveal differences in scale, comparison, study selection, or precision. Meta-analytic choices about multiple time points, correlated outcomes, small-study effects, missing data, and sponsorship deserve examination alongside significance testing. Fountoulakis et al. (2025) Popova et al. (2019)
A 2026 meta-analysis of randomized intravenous ketamine trials included 26 studies with 1,166 participants experiencing a major depressive episode and reported short-term improvement on depressive and suicidal symptom scales. That represents a valuable aggregate signal, but its abstract specifically notes that longer-term outcomes remain insufficiently established. Translating an acute standardized outcome into a safety-sensitive claim about population suicide prevention or indefinite maintenance would exceed these data. Moreover, reviews published in different years do not cover identical trial populations; later monotherapy trials may change the esketamine evidence landscape. Evidence synthesis should remain a continuously updated map of well-defined comparisons rather than a single definitive numerical score. Shim et al. (2026) Janik et al. (2025)
Treatment Resistance, Patient Selection, and Generalizability
Treatment resistance is not a single biological type: it can reflect pharmacological nonresponse, intolerance, poor access to adequate previous treatment, competing diagnoses, medical comorbidity, adherence difficulties, and psychosocial stressors. Trials use eligibility algorithms that turn this heterogeneous category into a research sample, often excluding psychosis, some substance-use disorders, unstable cardiovascular disease, and other clinically significant risks. Such exclusions improve internal safety and interpretation while reducing how readily average results can be generalized. The definition of adequate previous treatment should include appropriate duration, exposure, and clinical evaluation rather than assuming every reported failure was pharmacologically equivalent. Popova et al. (2019) Anand et al. (2023)
Age, baseline severity, past response, comorbid anxiety, concurrent psychotropic medication, and access to specialist monitoring may modify benefit, risk, or feasibility. Subgroup differences observed after the fact should be treated as exploratory unless adequately powered and prespecified. There is particular reason for caution with populations underrepresented in randomized pivotal studies, including children, many patients with complex substance-use histories, and people with unstable medical conditions. The U.S. label does not approve esketamine for pediatric treatment, and adult regulatory findings do not silently establish pediatric effectiveness or safety. DailyMed (2026) Popova et al. (2019)
Generalizability also depends on service infrastructure. A controlled treatment delivered in a trained center with repeated assessments and standardized monitoring is a joint product of the drug, clinical attention, selection, and procedural resources. Real-world inequities in transport, time off work, insurance coverage, availability of qualified personnel, and follow-up can change who receives treatment and who remains in care. Studying these factors is important for public health, but access inequalities do not justify exaggerating evidence or weakening supervision requirements. Implementation research should monitor both outcome representativeness and resource demands without confusing those observations with randomized evidence of drug efficacy. DailyMed (2026) European Medicines Agency (2025)
Pharmacokinetics, Enantiomers, Routes, and Exposure
Ketamine's clinical action depends on the relation among administered formulation, free systemic exposure, brain penetration, metabolic transformation, and the timing of receptor engagement. Intravenous administration delivers the parent drug directly to systemic circulation, whereas intranasal delivery introduces absorption variability and a different first-pass profile. The S-enantiomer and racemate cannot be considered equivalent simply by comparing nominal milligram amounts. Pharmacokinetic differences affect acute subjective intensity and potential adverse effects as well as the time course of clinical measurements. Reliable comparisons require concentration-time data, stereoselective assays where appropriate, and precise recording of coadministered medicines. DailyMed (2026) Popova et al. (2019)
Enantiomers may differ in affinity for pharmacological targets, disposition, and metabolic products. The parent compounds are further transformed to norketamine and hydroxynorketamine-related metabolites, which have attracted mechanistic interest. In animal experiments some metabolites produce behavioral effects that cannot be reduced to conventional NMDA channel inhibition; human therapeutic interpretation requires independent clinical evidence. The appearance of a metabolite in plasma proves exposure, not its causal sufficiency for antidepressant action. Analyses that simply correlate metabolite concentration with improvement are vulnerable to confounding by parent-drug exposure, hepatic metabolism, dose, treatment adherence, and posttreatment mediators. Zanos et al. (2016) DailyMed (2026)
The approved intranasal product is a standardized medicinal formulation with defined supervised administration and safety infrastructure. Compounded oral, sublingual, or nasal formulations can have different absorption, product-quality, and monitoring characteristics and lack the identical evidence package. Treating all administration routes as equivalent turns a set of clinically important exposure differences into a false generalization. The U.S. Food and Drug Administration has warned about risks associated with compounded ketamine products for psychiatric conditions, especially use without professional monitoring. Comparisons among formulations should remain tied to their own pharmacological and regulatory documentation. FDA (2023) DailyMed (2026)
Acute Tolerability: Dissociation, Sedation, and Cardiovascular Effects
Acute safety findings recur across randomized esketamine and ketamine research: dissociation, dizziness, nausea, perceptual changes, sedation, vertigo, altered bodily sensations, and transient increases in blood pressure. Their incidence varies with preparation, dose, patient characteristics, timing, and assessment instruments. In Popova and colleagues' trial, several of these events were more frequent with esketamine than nasal placebo, and withdrawals due to adverse events differed between arms. The consequences of these reactions are not exhausted by whether they resolve within the trial visit; they affect perceived treatment burden, physical safety, and the feasibility of repeated supervised sessions. Popova et al. (2019) Janik et al. (2025)
Current U.S. Spravato labeling carries boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors relevant to antidepressant treatment populations. Required observation lasts at least two hours after each administration; respiratory monitoring includes pulse oximetry. Blood pressure is checked around administration, and driving or hazardous machinery operation is restricted until the following day after restful sleep. The label also identifies important contraindications involving vascular disease or prior intracerebral hemorrhage. These are regulatory clinical safety requirements, not optional research decorations. Individual clinical protocols remain the responsibility of trained health professionals. DailyMed (2026)
The immediate altered-state effects may compromise blinding and also increase clinical vulnerability through reduced coordination, distorted perception, or impaired judgment. A well-designed study records the time course of subjective states, vital signs, concomitant medications, and adverse events with standardized scales and clearly defined thresholds. Open-label extension cohorts may underestimate harm if people with difficult early experiences discontinue before entering them. Clinical safety conclusions therefore combine blinded trials, extension data, postmarketing surveillance, and active investigation of events that are too rare to be reliably estimated in small experimental samples. DailyMed (2026) Zaki et al. (2025)
Long-Term Safety: Cognition, Urinary Function, and Repeated Exposure
Repeated exposure prompts questions distinct from acute infusion tolerability: cognitive trajectories, urinary tract symptoms, hepatic effects, tolerance, dependence, and whether clinical benefit continues to exceed accumulated burden. Studies of heavy nonmedical ketamine exposure describe clinically important urological and cognitive complications, but such populations differ materially from patients receiving regulated supervised treatment. Their findings are useful as risk signals and pathophysiological context, rather than direct incidence estimates for prescribed intranasal esketamine. Conversely, the absence of these events in a small four-week antidepressant trial cannot settle their probability during several years of treatment. DailyMed (2026) Zaki et al. (2025)
SUSTAIN-3 extended exposure observations over years in an open-label, single-arm treatment cohort of 1,148 adults with treatment-resistant depression. The final analysis reported 3,777 cumulative patient-years and a mean exposure of about 42.9 months, providing considerably more opportunity to observe common and some delayed events than acute pivotal trials. The investigators did not identify a new safety signal compared with prior evidence. However, people who enter and remain in an extension study are selected, independent randomized comparison is absent, and surveillance methods determine which harms can be detected. Longitudinal outcomes should therefore be described as informative observed safety data rather than proof of zero late risk. Zaki et al. (2025)
The contemporary U.S. label reports possible cognitive impairment and addresses ulcerative or interstitial cystitis, along with warnings relevant to abuse, misuse, and dependence. Studies of repeated clinical treatment should define standardized measures of memory, executive function, bladder symptoms, functional status, and discontinuation reasons at prespecified intervals. Stronger evidence would compare cumulative exposure groups and use active comparators with equivalent visit intensity. Pharmacovigilance records generate hypotheses, while well-designed longitudinal studies estimate clinical incidence and test exposure relationships more directly. Decisions about continuation depend on individualized specialist assessment and regulatory guidance, neither of which can be inferred from a general narrative monograph. DailyMed (2026) Zaki et al. (2025)
Abuse Liability, Dependence, and Clinical Governance
Ketamine and esketamine possess psychoactive properties that create abuse and misuse potential. In the United States, esketamine is a Schedule III controlled substance and its approved nasal formulation is supplied under a restricted risk-management program. Abuse risk is distinct from the fact of experiencing acute dissociation and must be examined using clinical history, patterns of exposure, drug-seeking behavior, and population-specific surveillance. The presence of misuse potential does not negate evidence of therapeutic efficacy; it changes the balance of risks and the setting in which treatment can responsibly be studied or administered. DailyMed (2026)
The U.S. Risk Evaluation and Mitigation Strategy requires certified healthcare settings and structured administration, restricting unsupervised patient possession of the product. Its purpose includes managing serious risks associated with sedation, dissociation, and respiratory depression. Procedural requirements are part of what a real-world intervention consists of; studies performed in such settings estimate outcomes of a drug under observation, not outcomes of private use without supervision. The Food and Drug Administration has separately warned that compounded ketamine products used at home for psychiatric purposes may expose patients to sedation, dissociation, psychiatric events, respiratory compromise, and changes in blood pressure without the protections of a recognized drug-approval framework. DailyMed (2026) FDA (2023)
Dependence requires careful conceptual definition. Pharmacological tolerance, withdrawal phenomena, psychological reliance on an altered state, problematic patterns of obtaining treatment, and established substance-use disorder represent distinct constructs. Their rates cannot be inferred from one another or from a manufacturer's statement about routine tolerability. Future observational programs should record dose escalation, unscheduled access, discontinuation outcomes, diagnostic changes, and longer-term quality of life. Transparent reporting of both therapeutic successes and concerning behaviors supports more discriminating risk estimates, particularly for patients with previous substance-use vulnerability who may have been underrepresented in randomized trials. DailyMed (2026) Zaki et al. (2025)
Regulatory Evidence: United States, Europe, and Clinical Recommendations
Regulatory authorization has a specific scope. The current U.S. prescribing information for Spravato lists adult treatment-resistant depression as a monotherapy or in combination with an oral antidepressant. It also lists treatment of depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior in conjunction with an oral antidepressant, while explicitly stating that effectiveness for preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. The document was revised in March 2026 and the DailyMed record updated in July 2026. These facts establish the applicable U.S. labeling as reviewed here, not a universal rule for every country or clinical setting. DailyMed (2026)
The European Medicines Agency describes Spravato as a supervised prescription product used alongside an SSRI or SNRI for adults with treatment-resistant major depressive disorder following unsuccessful adequate antidepressant treatments. Regional conditions therefore differ from the expanded U.S. monotherapy indication. Similarly, clinical guideline bodies may make narrower recommendations than regulators because they also evaluate comparative effectiveness, organization of care, and economic feasibility. A drug may be authorized, yet a health system may limit routine reimbursement or recommend additional specialist review. Scientific writing should identify which authority is speaking and the date of the relevant rule. European Medicines Agency (2025) DailyMed (2026)
Intravenous racemic ketamine is separately authorized for anesthetic purposes in the United States; the intravenous antidepressant protocols discussed in many trials are off-label uses. The scientific evidence for a treatment can be meaningful while its legal indication remains distinct. Reporting this accurately prevents an implicit claim that every dose, route, and protocol has the same regulatory approval. Likewise, experimental indications for obsessive-compulsive disorder or other diagnoses should be presented as research even when preliminary signals are favorable. Clinically sensitive publication requires the latest regulator statements, a clear distinction between evidence and authorization, and a qualified professional review of recommendations that might influence patient safety. DailyMed (2026) Rodriguez et al. (2013)
Special Populations, Contraindications, and Pharmacological Interactions
Risk-benefit inference changes when a patient has cardiovascular or cerebrovascular vulnerability, pulmonary disease, hepatic impairment, pregnancy potential, or substantial exposure to other psychoactive medicines. Esketamine labeling details contraindications and warnings relevant to such circumstances, including transient blood-pressure increases, cognitive and motor impairment, and pregnancy-related risk. It also warns about interactions with central nervous system depressants and agents that may increase blood pressure. The presence of a warning signals a need for professional evaluation; its scientific meaning should be traced to clinical trials, pharmacology, and postmarketing evidence rather than converted into an undifferentiated blanket statement about every individual. DailyMed (2026)
Children and adolescents require a separate evidentiary framework from adults. The current U.S. label states that Spravato is not approved for pediatric patients, and an adult treatment-resistant depression trial cannot establish developmental efficacy or safety in a younger population. Likewise, the validity of randomized outcomes in older adults depends on their representation and the specific adverse-event profile. Pregnancy and lactation are not simply extensions of adult antidepressant efficacy, because placental exposure and developing physiology generate different outcomes and ethical constraints. Published labels and studies should be consulted directly in each setting. DailyMed (2026)
Concomitant treatment can influence both efficacy and adverse effects. Studies that initiate a new oral antidepressant in both arms estimate the esketamine increment within that combination, and treatment with sedatives or stimulants may change acute monitoring needs. Other therapy and structured psychosocial care can continue during study participation, affecting long-term outcomes and contextual mechanisms of recovery. Clinical reasoning therefore addresses interactions and the total treatment package, while experimental interpretation distinguishes these cointerventions from the randomized contrast. This distinction is essential when comparing early adjunctive trials with later monotherapy trials and with real-world cohorts. Popova et al. (2019) Janik et al. (2025) DailyMed (2026)
Beyond Major Depression: Obsessive-Compulsive Symptoms and Other Exploratory Indications
Experimental use of ketamine in obsessive-compulsive disorder arises partly from hypotheses about glutamate-related cortico-striatal circuitry and the limitations of existing treatments for some patients. Rodriguez and colleagues' 2013 double-blind crossover study enrolled fifteen medication-free adults with near-constant obsessions; carryover complicated the planned crossover comparison, so the authors analyzed first-period outcomes separately. The reported preliminary reductions in obsession-related symptoms generated interest in a rapid glutamatergic strategy. A fifteen-person experimental trial, however, cannot establish a broad treatment indication, routine efficacy, durable functional improvement, or long-term safety for obsessive-compulsive disorder. Rodriguez et al. (2013)
Subsequent small studies and exploratory designs have further examined the obsessive-compulsive signal, sometimes using active controls and different routes. Heterogeneity of samples, blinding, concomitant care, and rating periods makes cumulative inference difficult. A promising short-term outcome requires replication in adequately powered randomized parallel-group studies, assessment of durable OCD-specific symptom changes, and explicit comparison with established evidence-based interventions. Research on obsessional symptoms may ultimately illuminate the transdiagnostic relevance of glutamate signaling, but it should remain separate from an approved depression indication and from a claim that every disorder marked by repetitive thinking responds to the same intervention. Rodriguez et al. (2013) DailyMed (2026)
Proposed applications in bipolar depression, post-traumatic stress symptoms, chronic pain-associated distress, and additional psychiatric contexts involve different populations and outcome constructs. The strength of evidence cannot be imported wholesale from treatment-resistant unipolar depression. Comorbidity, mania risk, previous substance exposure, and concurrent treatment may alter the study question. Rather than extending a general-purpose efficacy claim to every diagnostic category, an informative research program builds disorder-specific randomized protocols, specifies appropriate controls, and measures both patient-important outcomes and events particular to that population. Each new application must pass its own efficacy, safety, and regulatory threshold. Zarate et al. (2006b) DailyMed (2026)
Phenomenology, Expectancy, and the Psychology of Treatment
Ketamine's subjective effects place experimental psychology inside the evaluation of a pharmacological intervention. Patients may report alterations in bodily self-experience, sensory salience, time perception, and emotional perspective during acute exposure. These experiences can influence treatment expectations, perceived therapeutic meaning, anxiety during sessions, and the willingness to return. A theory of treatment that attends only to molecular antagonism misses potentially important explanatory and safety-related processes; one that assumes subjective intensity itself causes antidepressant recovery commits the opposite inferential error. Measuring both drug-related experience and later outcomes allows their relations to be tested. Murrough et al. (2013a) DailyMed (2026)
Expectancy is especially difficult to separate from pharmacological effect because drug-related sensations can reveal group assignment. An active placebo partly addresses unequal medication experience but might not match dissociation, and any perceptible control has independent neurophysiological properties. Participants' prior beliefs about a novel intervention may change effort, reporting, and willingness to engage in behavioral recovery during follow-up. Researchers can collect treatment-guessing and expectancy measurements, compare independent blinded raters with patient reports, and vary supportive contact across well-designed conditions when ethically appropriate. Such methods clarify the extent to which observed efficacy depends on a distinctive clinical setting rather than erasing the role of the drug. Murrough et al. (2013a) Fountoulakis et al. (2025)
Changes in self-narrative and perceived agency following symptom reduction deserve study as outcomes in their own right. When a person experiences a marked improvement after years of severe depression, renewed planning, relational engagement, and expectations about the future may become possible. These downstream developments may be psychologically meaningful regardless of whether dissociation was causal. Their measurement requires longitudinal instruments that distinguish relief in mood severity from everyday function and relational participation. Such questions connect psychopharmacology to clinical psychology without allowing theoretical descriptions of identity or subjective experience to replace reproducible clinical evidence. Anand et al. (2023) Daly et al. (2019)
Evidence Appraisal: Bias, Missingness, and Clinical Meaning
Evidence strength is a property of a specified inference rather than an attribute assigned to a publication as a whole. Randomized allocation provides a strong basis for estimating the comparative short-term effects of the assigned treatment package, subject to deviations, missing outcomes, and measurement error. Yet the same trial may provide weak evidence for a molecular mediator, long-term safety, or transportability to excluded patients. For ketamine and esketamine, the most informative distinctions concern comparator quality, acute psychoactive unblinding, systematic use of background medication, prospective definition of resistance, and long-term retention. A study's positive primary endpoint deserves analysis alongside the exact counterfactual it creates. Murrough et al. (2013a) Popova et al. (2019)
Missingness is particularly consequential in maintenance cohorts, where discontinuation can be related to poor efficacy, adverse effects, inconvenience, or clinical improvement. Intention-to-treat analysis preserves the original randomized comparison when appropriately implemented, whereas completer analyses answer more selective questions. Sensitivity analyses can test plausible deviations from missing-at-random assumptions. Open-label extension outcomes should report exposure time, events per person-time where appropriate, study exit reasons, and the denominators from which percentages are derived. Without these details, simple statements that treatment remained successful for many years are susceptible to survivorship and selection bias. Daly et al. (2019) Zaki et al. (2025)
Statistical significance does not settle clinical importance. A four-point mean difference on a depression scale may coexist with a distribution of major responders, modest responders, and nonresponders. Clinical interpretation should consider baseline burden, response and remission definitions, quality of life, treatment burden, and harms. Noninferiority demands a justified prespecified margin and fidelity to relevant analysis populations; active-treatment superiority requires attention to open-label performance and outcome-assessment masking. These considerations are illustrated by the different estimands of the esketamine add-on trial, ELEKT-D, and ESCAPE-TRD. Popova et al. (2019) Anand et al. (2023) Reif et al. (2023)
Replicability, Publication Bias, and Independence of Evidence
Replicability includes more than repeating a positive symptom difference: a complete replication requires comparable population selection, exposure, comparator, measurement, and analysis rules. Independently conducted studies can reveal whether outcomes depend on investigator expertise, sponsor infrastructure, or treatment setting. Trials of ketamine span academic groups and distinct designs, whereas many pivotal esketamine trials belong to a coordinated commercial development program. This is a meaningful feature of research provenance and supports careful conflict-of-interest disclosure, independent reanalysis, and replication rather than automatic dismissal of regulated trial data. Zarate et al. (2006b) Murrough et al. (2013a) Popova et al. (2019)
Publication bias may arise when positive small trials are more likely to enter the published record, while selective outcome reporting can amplify an apparent early advantage. Prespecified primary outcomes, public trial registries, accessible protocols, and complete adverse-event reporting improve trustworthiness. Meta-analyses can examine small-study patterns, but their diagnostics are often underpowered and confounded by clinical heterogeneity. Comparisons between early large effects and later smaller or varied estimates should therefore motivate scrutiny of control conditions and sample selection. A scientific synthesis has to preserve negative evidence and unexpected results, including the limited antidepressant signal for other NMDA-active compounds such as memantine. Fountoulakis et al. (2025) Zarate et al. (2006a)
Claim-to-source tracing is a further requirement. Numerical efficacy estimates should be drawn from the actual corresponding study rather than recycled across reviews without context. For example, the placebo-adjusted response found at twenty-four hours in an intravenous active-control trial differs from the difference at day twenty-eight in an intranasal adjunctive trial. Safety statements must distinguish randomized observation from postmarketing reports. Where only abstracts are accessible, the article's methods or supplemental analyses should not be represented as directly examined. A complete scientific audit documents the study population, comparator, time point, outcome, and provenance for each headline claim. Murrough et al. (2013a) Popova et al. (2019) DailyMed (2026)
Neurobiological Mediation and the Translational Research Agenda
A credible model of rapid antidepressant action must bridge several causal levels. At the pharmacological level, investigators measure drug and metabolite exposure and receptor or channel effects. At the neural level, they measure network activity, plasticity-related changes, and systems involved in affective regulation. At the clinical level, they assess symptom trajectories and functional outcomes. Demonstrating that all three change during treatment is insufficient for mediation: the proposed intermediate must be tested with temporal ordering, control of confounding, and where feasible selective manipulation. Ketamine research illustrates how exciting preclinical results can precede the evidence needed to claim a specific mechanism in people. Li et al. (2010) Zanos et al. (2016)
Studies should test whether early neural signatures predict later improvement after controlling for baseline illness severity and dose, and whether the same signatures are observed under independent drugs or circuit interventions. The principal difficulty is that neural markers may reflect the altered acute state rather than the processes producing sustained recovery. Time-resolved designs that sample before dosing, during acute effects, after perceptual recovery, and at later clinical intervals can help disambiguate these possibilities. However, multiple testing, imperfect proxy measures, and reverse causation remain serious concerns. A mechanistic biomarker becomes useful when it adds reproducible predictive information and clarifies causal pathways rather than merely correlating with change. Li et al. (2010) Janik et al. (2025)
Pharmacological perturbation of the opioid system and experimental testing of ketamine metabolites exemplify promising mechanistic tests that also require replication and triangulation. Investigators should explicitly separate necessity, sufficiency, and moderation. An experimental manipulation may attenuate an effect without accounting for all of it; a metabolite may reproduce a phenotype in an animal without being clinically sufficient in humans. Genetic, pharmacological, and circuit-specific approaches can provide convergent evidence only when their assumptions are evaluated independently. The scientific objective is a multi-level explanatory model able to predict intervention response, adverse phenomena, and clinically important variation with known uncertainty. Williams et al. (2018) Zanos et al. (2016)
Comparative Treatment Strategy and Health-System Evaluation
Rapid symptom change has value only within a care pathway that can maintain safety and address continuing psychosocial needs. Comparative treatment science therefore asks who benefits from a supervised glutamatergic intervention relative to electroconvulsive therapy, medication augmentation, psychotherapy, and other available approaches, considering both short-term improvement and longer-term functioning. The ELEKT-D and ESCAPE-TRD trials have different designs and should not be combined into a simplistic rank order. Their findings support evaluation of treatment choice in defined patient groups and highlight the importance of patient preferences, cognitive outcomes, adverse effects, and treatment availability. Anand et al. (2023) Reif et al. (2023)
Service-delivery research can test the effects of visit frequency, supervised observation logistics, continuity of care, and follow-up scheduling on adherence and outcomes. Costs must include clinical time and infrastructure as well as medication acquisition, and economic analyses should specify jurisdiction, payer perspective, and effectiveness assumptions. A treatment that reduces symptoms quickly may still impose considerable travel and observation burdens. Similarly, an intervention with a favorable comparison in one trial may be inaccessible in underresourced regions. These are measurable health-service characteristics that shape effective access and population benefit. European Medicines Agency (2025) DailyMed (2026)
Patient-centered endpoints should extend beyond mean symptom severity to ordinary functioning, personal goals, cognitive performance, relational life, treatment acceptability, and sustainable engagement with care. Their incorporation does not weaken pharmacological rigor; it tests whether observed effects matter beyond the scale on which a trial was powered. The rapid treatment setting also creates opportunities to study psychological learning, renewed motivation, and subsequent behavioral activation. Such changes can be consequences of improved mood, contributors to maintenance, or aspects of care unrelated to the initiating receptor mechanism. Appropriately designed longitudinal comparisons can begin to separate these roles. Anand et al. (2023) Daly et al. (2019)
Artificial Era: Computational Measurement and Boundaries of Explanation
The Artificial Era introduces new methodological possibilities for studying treatment trajectories through digital symptom sampling, adaptive longitudinal models, and computational analysis of heterogeneous response patterns. These methods can reveal temporal profiles hidden by widely spaced clinic visits, provided that the meaning of each measure is established and that collection respects privacy and participant autonomy. Algorithms can assist in modeling associations between baseline characteristics and later response, but predictive accuracy in training data is not evidence of a validated treatment-selection mechanism. External prospective validation and evidence of clinically useful decision impact are required. Janik et al. (2025) Popova et al. (2019)
Human–Artificial research partnerships may also improve literature surveillance and reproducible extraction of trial designs, outcome definitions, regulatory changes, and bibliographic provenance. A machine-mediated research workflow is scientifically valuable when its assertions remain linked to checkable primary sources and error correction is documented. Machine-generated synthesis can facilitate comparison across jurisdictions and study populations, while qualified clinical professionals remain responsible for patient-specific safety judgments. The research value of Artificial in this context lies in organizing, testing, and preserving knowledge with transparent methods. It does not establish novel pharmacological effects by declaration. Fountoulakis et al. (2025) DailyMed (2026)
Computational research in this field should specify the unit of analysis and guard against leakage between training and validation cohorts, uneven treatment selection, and outcomes observed only among patients who continue treatment. Models trained in specialist centers may learn institution-specific referral pathways rather than portable biological predictors. Their uncertainty should be reported across demographic and clinical subgroups. The most promising future integration combines controlled experimental pharmacology, independent clinical studies, repeated patient-reported measurement, and interpretable statistical inference. This is an interdisciplinary research program within psychology and psychopharmacology, not an alternative to validation in human populations. Daly et al. (2019) Zaki et al. (2025)
Open Questions and Priority Experimental Programs
The first open problem is identifying which molecular and circuit events are necessary for clinically important rapid benefit and which merely accompany intoxication or recovery. Progress requires controlled mechanistic perturbations, stereoselective exposure measurement, reliable biomarkers, and designs that separate acute subjective effects from longer symptom change. The second concerns prediction: which clinical, psychological, and biological characteristics reproducibly identify responders, early relapsers, or people at particular safety risk? Small exploratory correlations cannot establish clinical selection rules. Research should predefine hypotheses and validate them independently before translating them into personalized care claims. Li et al. (2010) Williams et al. (2018)
The third problem is maintenance. Studies should compare sustained strategies, treatment intervals, continuation against well-chosen alternatives, and protocols for managing discontinuation with prospective outcomes over years. Long open-label cohorts offer exposure data, but randomized and robust observational comparisons remain needed to distinguish treatment effect from selection and changing background care. The fourth is measuring benefit and harm together: neurocognition, urinary symptoms, cardiovascular effects, misuse risk, functional recovery, and quality of life should be assessed systematically. Rare but serious events require collaboration across sites and postmarketing follow-up rather than reliance on small trials. Daly et al. (2019) Zaki et al. (2025) DailyMed (2026)
The fifth concerns acute suicidal risk and the precise outcomes that can legitimately be claimed. Trials should distinguish depression severity, suicidal thoughts, attempts, and death, while maintaining comprehensive clinical care and ethical safeguards. The sixth concerns comparative implementation, including independent trials against relevant treatments and evaluation of access inequalities. The seventh is geographic and demographic generalizability, especially in patient groups usually excluded from pivotal studies. Each research priority should specify a testable claim, design, measurement schedule, uncertainty, and safety oversight. The field advances when its mechanistic explanations and clinical promises are constrained by the strength of their corresponding evidence. Abbar et al. (2022) Shim et al. (2026) Anand et al. (2023)
Critical Scientific Synthesis
The established scientific contribution of ketamine research is the demonstration that a relatively brief pharmacological perturbation can be followed by marked, sometimes rapid changes in depressive symptom ratings under randomized conditions. The strongest initial demonstrations include carefully designed intravenous comparisons, with the active-control trial offering a more demanding inference than saline-based studies alone. Intranasal esketamine has a distinct body of randomized clinical evidence for treatment-resistant depression, including adjunctive and more recent monotherapy trial designs, and controlled maintenance evidence among previously stabilized patients. These are related bodies of evidence, each with intervention-specific limits. Murrough et al. (2013a) Popova et al. (2019) Janik et al. (2025) Daly et al. (2019)
At the mechanistic level, NMDA receptor antagonism is a well-characterized initiating pharmacological action, while AMPA-dependent responses, mTOR-linked plasticity, metabolite actions, and possible opioid-system contributions represent a partially resolved explanatory network. The causal steps from these laboratory findings to clinical remission in individual humans remain under investigation. The most informative synthesis recognizes both the biological plausibility of multiple pathways and the incompleteness of direct human mediation tests. A scientifically mature field distinguishes evidence of target engagement, evidence of clinical improvement, and evidence that the target caused improvement through a specified neural route. Li et al. (2010) Zanos et al. (2016) Williams et al. (2018)
The clinical interpretation integrates short-term efficacy with supervision, adverse effects, repeated treatment, and jurisdiction-specific approvals. There is evidence of rapid reduction in suicidal ideation measures in selected intravenous trials, but it does not establish suicide prevention, and U.S. esketamine labeling is explicit about limitations concerning suicidal ideation, behavior, and mortality. SUSTAIN-3 supplies meaningful extended safety observation while its uncontrolled design restricts causal claims about persistent efficacy. The most responsible account of the field therefore preserves clinically important benefits, known safety requirements, disputed mechanistic interpretations, and unresolved questions of durability and generalizability within one evidence structure. Abbar et al. (2022) DailyMed (2026) Zaki et al. (2025)
Conclusion
Ketamine, esketamine, and rapid-acting glutamatergic treatment constitute a significant research domain at the intersection of experimental pharmacology, affective neuroscience, clinical psychology, and psychiatric treatment. The field arose from controlled demonstrations of unexpectedly rapid symptom change and developed through larger randomized trials, mechanistic studies, regulated intranasal treatment programs, comparative effectiveness investigations, and longitudinal follow-up. Intravenous racemic ketamine and intranasal esketamine must retain their distinct scientific identities because formulation, route, trial population, comparator, and authorization status differ. The results establish clinically meaningful possibilities for some adults with treatment-resistant depression while preserving large individual variation. Berman et al. (2000) Murrough et al. (2013a) Popova et al. (2019)
The scientific interpretation is strongest when it separates receptor antagonism from downstream neuroplasticity hypotheses, acute improvement from relapse prevention, ideation scores from suicidal behavior, and study-specific efficacy from wider clinical implementation. Randomized clinical evidence supports defined treatment comparisons; pharmacological and neural mediation demands additional experiments; long-term safety and benefit require sustained observation and independent evaluation. The contemporary FDA and European regulatory documents provide essential jurisdiction-specific boundaries, and qualified clinical oversight is intrinsic to safe use of the regulated intranasal product. Daly et al. (2019) DailyMed (2026) European Medicines Agency (2025)
The resulting research agenda combines mechanistic precision, replication, patient-centered outcomes, independent comparative trials, longitudinal safety measurement, and equitable health-system evaluation. New computational research tools can strengthen evidence organization and prediction when their results are externally validated. The central lesson of this monograph is methodological as well as therapeutic: a fast observable change is a major scientific discovery, and its lasting explanation and safe use depend on a sequence of separately testable claims. This integrated perspective defines the research object and places rapid glutamatergic treatment within the broader scientific architecture of psychology. Fountoulakis et al. (2025) Shim et al. (2026) Zaki et al. (2025)
References
- Abbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., Fabbro, P., & Jollant, F. (2022). Ketamine for the acute treatment of severe suicidal ideation: Double blind, randomised placebo controlled trial. BMJ, 376, e067194. https://doi.org/10.1136/bmj-2021-067194
- Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry, 57(3), 270–276. https://doi.org/10.1001/archpsyc.57.3.270
- Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., Collins, K. A., Costi, S., Iqbal, S., Jha, M. K., Krishnan, K., Malone, D. A., Nikayin, S., Nissen, S. E., Ostroff, R. B., ... Hu, B. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388, 2315–2325. https://doi.org/10.1056/NEJMoa2302399
- Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354. https://doi.org/10.1016/S0006-3223(99)00230-9
- Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry, 175(7), 620–630. https://doi.org/10.1176/appi.ajp.2018.17060720
- Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., Thase, M. E., Zajecka, J., Winokur, A., Divacka, I., Fagiolini, A., Cubala, W. J., Bitter, I., Blier, P., Shelton, R. C., ... Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189
- European Medicines Agency. (2025). Spravato (esketamine): European public assessment report and therapeutic indication (overview updated September 10, 2025). https://www.ema.europa.eu/en/medicines/human/EPAR/spravato
- Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025). Esketamine treatment for depression in adults: A PRISMA systematic review and meta-analysis. American Journal of Psychiatry, 182(3), 259–275. https://doi.org/10.1176/appi.ajp.20240515
- Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Macaluso, M., Mattingly, G. W., Shelton, R. C., Zajecka, J. M., & Fu, D.-J. (2025). Esketamine monotherapy in adults with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 82(9), 877–887. https://doi.org/10.1001/jamapsychiatry.2025.1317
- Janssen Pharmaceuticals, Inc. (2026). Spravato (esketamine) nasal spray, prescribing information (revised March 2026; DailyMed updated July 29, 2026). National Library of Medicine, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964. https://doi.org/10.1126/science.1190287
- Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
- Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry, 74(4), 250–256. https://doi.org/10.1016/j.biopsych.2012.06.022
- Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
- Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., & Godinov, Y. (2023). Esketamine nasal spray versus quetiapine for treatment-resistant depression. New England Journal of Medicine, 389(14), 1298–1309. https://doi.org/10.1056/NEJMoa2304145
- Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology, 38, 2475–2483. https://doi.org/10.1038/npp.2013.150
- Shim, S. R., Jeong, H. S., Bommersbach, T. J., Nierenberg, A. A., Zarate, C. A., Jr., Kaster, T. S., Correll, C. U., McIntyre, R. S., Krystal, J. H., & Rhee, T. G. (2026). Ketamine infusions and rapid reduction of suicidal and depressive symptoms in major depressive episode: A systematic review and meta-analysis. JAMA Psychiatry, 83(7), 714–731. https://doi.org/10.1001/jamapsychiatry.2026.0612
- Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., Kurian, B., Winokur, A., Fava, M., Manji, H., Drevets, W. C., & Van Nueten, L. (2016). A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. American Journal of Psychiatry, 173(8), 816–826. https://doi.org/10.1176/appi.ajp.2016.16010037
- U.S. Food and Drug Administration. (2023, October 10). FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. Compounding risk alerts. https://www.fda.gov/drugs/human-drug-compounding/compounding-risk-alerts
- Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., & Schatzberg, A. F. (2018). Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. American Journal of Psychiatry, 175(12), 1205–1215. https://doi.org/10.1176/appi.ajp.2018.18020138
- Zaki, N., Chen, L. N., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Young, A. H., Lacerda, A. L. T., Paik, J.-W., Popova, V., & Fu, D.-J. (2025). Safety and efficacy with esketamine in treatment-resistant depression: Long-term extension study. International Journal of Neuropsychopharmacology, 28(6), pyaf027. https://doi.org/10.1093/ijnp/pyaf027
- Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., Dossou, K. S. S., Fang, Y., Huang, X.-P., Mayo, C. L., Wainer, I. W., Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate, C. A., Jr., & Gould, T. D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481–486. https://doi.org/10.1038/nature17998
- Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864. https://doi.org/10.1001/archpsyc.63.8.856
- Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry, 163(1), 153–155. https://doi.org/10.1176/appi.ajp.163.1.153